Eleven new drugs with blockbuster potential are expected to launch this year; a bill would require FDA to quickly review drugs approved in the EU; Biogen reinforces its focus on hard-to-treat diseases
BI rare-disease awareness push slated for Saturday
February 26, 2015
6:30 pm
Industry rare disease awareness efforts included a pipeline overview at Pfizer as well as BI’s efforts to draw attention to IPF.
NPS drug approval bolsters Shire acquisition decision
The FDA approved NPS Pharmaceuticals’s rare-disease drug Friday. The company, which Shire shelled out $5.2 billion to buy, expects it to hit the market during the second-quarter.
Mallinckrodt plans expansion of commercial staff
January 8, 2015
8:49 pm
The specialty biopharma firm says it’s hiring new commercial managers after a buying spree.
Five things for pharma marketers to know: Monday, November 24
BioMarin to acquire Dutch biotech Prosensa; Woodcock says significant efficacy key to Breakthrough Therapy designation; Stryker considers $16 billion bid for UK devicemaker Smith and Nephew.
Rethinking Healthcare Communications Through the Prism of Rare Diseases
Success today is predicated on recognizing that every patient is different, every disease is different, every drug, every breakthrough and every cure is different.
The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced “on par” with Cerezyme, which goes for around $300,000 a year in the US.
